Hemab Therapeutics Holdings Inc. (COAG) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Hemab Therapeutics Holdings Inc., updated every trading day.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Hemab Therapeutics Holdings Inc. (COAG) is a Health Care company in Biotechnology: Biological Products (No Diagnostic Substances), worth $1.8B. It trades at $38.50, up 0.26% today. Its overall quality score is 54 out of 100, ranked against the whole US market. 4 analysts' average target of $62.50 implies +62.3% from today's price. Kronos AI's 30-day forecast is +4.1% (6 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $62.50 |
| Low – high | $56.00 – $70.00 |
| Analysts | 4 |
| Upside to average | +62.3% |
Kronos AI 30-day forecast
| Expected close | $39.98 (+4.1%) |
| Likely range | −3.7% … +20.8% |
| As of | 2026-10-27 |
Quality scores
| Profitability | 50 |
| Solvency | 68 |
| Growth | 44 |
| Overall | 54 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Halal Health Care stocks · Zakat calculator · Purification calculator